← Back to headlines
CytomX Receives FDA Fast Track Designation for Colorectal Cancer Drug
Biotech firm CytomX Therapeutics has been granted Fast Track status by the FDA for its experimental antibody-drug conjugate targeting colorectal cancer.
27 Aug, 15:34 — 27 Aug, 15:34
Sources
Showing 1 of 1 sources
